Supplementary Figure S2 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer

Carlotta Antoniotti; Alessandra Boccaccino; Robert S. Seitz; Mirella Giordano; Aurélie Catteau; Daniele Rossini; Filippo Pietrantonio; Lisa Salvatore; Kimberly McGregor; Francesca Bergamo; Veronica Conca; Simone Leonetti; Federica Morano; Giorgio Papiani; Emiliano Tamburini; Maria Bensi; Sabina Murgioni; Douglas Teller Ross; Alessandro Passardi; Isabelle Boquet; Tyler J. Nielsen; Jérôme Galon; Matthew G. Varga; Brock L. Schweitzer; Chiara Cremolini

doi:10.1158/1078-0432.27030781

Abstract

Kaplan Meier estimates of progression-free survival in the overall population (optimized cut-point), according to IO status (a) and to both IO status and treatment arm (b). Legend: HR: hazard ratio, NR: not reached. Control arm indicates FOLFOXIRI plus bevacizumab. Atezo arm indicates FOLFOXIRI plus bevacizumab and atezolizumab.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Antoniotti et al. (2024) studied this question.

synapsesocial.com/papers/68e587eeb6db643587523e4c https://doi.org/10.1158/1078-0432.27030781

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure S2 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer

Abstract

Discussion

Cite This Study

Supplementary Figure S2 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer

Abstract

Discussion

Cite This Study

Keep reading

Keep reading